Persistent muscle stromal cells may erase lifespan gains from fasting mimetics
The hypothesis proposes that fasting mimetics lose their lifespan benefit when blocked muscle recovery lets repair-supporting cells persist and drive scarring. Normal cell numbers and fates, together with no benefit from selectively limiting these cells, would argue against this mechanism.
Stage of verification
- Hypothesis published2026-10-06
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Stem cell
Fibroadipogenic progenitor cells
A progenitor cell population that provides local signals supporting muscle formation
Where this hypothesis actsMuscle after repair between fasting-mimetic cycles, when anabolic recovery is suppressed
Hypotheses on this target 1
Reprogramming
Transplantation
Directed differentiation
Proliferation
Population balance
What is proposed
Return their abundance to the physiological range
HowBriefly and selectively limit their survival after repair, confirming local action and preservation of beneficial progenitors
Possible result
Possible restoration of lifespan extension despite continued suppression of muscle protein synthesis
From the recordНовый миметик мог бы воспроизводить физиологическое сокращение временной стромальной популяции после ремонта, например посредством краткого, избирательного ограничения её выживания.
Metabolism and energy
Protein translation
The process by which cells synthesize proteins
Where this hypothesis actsMature muscle fibers during recovery between fasting-mimetic cycles
Hypotheses on this target 6
Inhibition1
Activation
Function preservation
Supplementation
Feedback restoration
Direct measurement
What is proposed
Suppress recovery of protein synthesis between cycles
HowNot stated in the record
Possible result
Expected progenitor accumulation followed by fibrosis and loss of lifespan extension unless cell abundance is corrected
From the recordИзбирательное возвращение их численности к физиологическому диапазону восстановит выигрыш жизни при сохранённом подавлении мышечного синтеза белка.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
A treatment that imitates fasting might extend life only if muscle finishes recovering between treatments. The unexpected move is to blame repair-supporting cells that remain after their useful work should have ended, and to propose briefly limiting their survival. This is a hypothesis generated by the pipeline, not a measured explanation of lifespan extension.
- Repeated fasting-mimicking treatment is proposed to require muscle rebuilding between treatment periods.
- Recovered muscle fibres would stop sustaining conditions of continuing injury, allowing repair-supporting precursor cells to return to their usual numbers.
- Blocking muscle rebuilding would switch those cells from a temporary repair population to a population that persists and accumulates across treatment periods.
- The persistent population would shift muscle repair toward scar formation.
- This change in muscle would erase the lifespan benefit despite unchanged suppression of the treatment's main target elsewhere.
- Briefly and selectively limiting the retained cells' survival would return their numbers to normal and restore the lifespan benefit despite continued suppression of muscle protein production.
A repair crew arrives after each leak, but the old crew never leaves before the next one arrives. Eventually, the accumulated scaffolding obstructs the building it was meant to repair.
Where the picture breaks: The cells can change what they become and how they affect neighbouring cells; their number alone does not describe their effects. Removing useful repair cells could also impair recovery, and the picture cannot establish any effect on lifespan.
- Master questionstep 01 of 04
Imitating selected processes that normally occur in the body could provide new ways to extend life.
Rests on: The supplied goal calls for hypotheses about substances, combinations or other interventions that reproduce useful effects of normal bodily processes.
Stated in the chain - Goal pillarstep 02 of 04
Repeated treatments may need to reproduce a complete response, including its recovery phase.
Rests on: The goal motivates imitating useful bodily processes, but does not itself establish that completing each response determines the benefit of repeated treatment.
AssumptionCompletion of the response between treatments is taken as a relevant condition for developing a treatment that extends life.
- Gap questionstep 03 of 04
A fasting mimetic, a treatment that reproduces some effects of fasting, might lose its lifespan benefit if muscle anabolism, the building of muscle components including proteins, cannot recover between treatments.
Rests on: The preceding stage identifies completion between repeated responses as the issue. This stage makes muscle rebuilding the specific recovery phase to examine, while holding suppression of the treatment's main target in other tissues unchanged.
Stated in the chain - Hypothesisstep 04 of 04
Fibro-adipogenic progenitors, muscle-resident precursor cells that can produce scar-forming or fat cells, are proposed to persist when muscle rebuilding is blocked. Their persistence would shift repair toward fibrosis, the accumulation of scar tissue, and erase the lifespan benefit; selectively returning their numbers to normal would restore it.S3
Rests on: The preceding stage supplies the interrupted muscle-recovery scenario. Stem Cell Reports (2024), source S3, describes a connection between failed removal of these precursor cells and scarring after acute muscle injury in mice; it does not establish that blocking muscle rebuilding causes their persistence during repeated fasting-mimicking treatment, or that this changes lifespan.
Supported by literature
What is carried, and what is not. Screened sources speak to two local connections: retained repair-supporting cells can contribute to scarring, and reducing these cells can reduce scarring. Stem Cell Reports (2024), S3, addresses the first after acute injury in mice, while Bone & Joint Research (2026), S7, reports reduced scarring after cell depletion in two mouse injury models, with functional improvement in only one; neither establishes the proposed sequence from blocked rebuilding through repeated cell accumulation to lost lifespan benefit.S3S7
Where the reasoning is carried by something unstated · 1
- Goal pillar. Completion of the response between treatments is taken as a relevant condition for developing a treatment that extends life.
How a result here could mislead · 3
- A lifespan change after limiting these cells could be credited to removal of the proposed muscle population even if the intervention also affects other tissues or removes useful repair cells. What closes it: The supplied proposal explicitly requires confirmation that the intervention stays local and preserves useful precursor cells. Cell identity, abundance and eventual fate must be tracked, alongside continued suppression of muscle protein production and unchanged action on the treatment's main target elsewhere.
- Shorter survival after blocking muscle rebuilding could be mistaken for loss of the fasting-mimicking treatment's added benefit, although the muscle intervention could shorten survival independently. What closes it: The lifespan comparison must include animals with the same muscle intervention receiving control treatment. The proposal must distinguish the fasting-mimicking treatment's additional benefit from the survival cost of blocking recovery.
- Less scarring could be read as restoration of lifespan benefit, while failure to restore lifespan could be read as rejection even if cell numbers were never corrected or correction began after the proposed persistent state had formed. What closes it: Measure lifespan separately from scarring, verify that cell numbers return to a defined normal range, and establish when correction occurs relative to accumulation and scar formation. The supplied material provides no numerical normal range or timing boundary; these must be fixed before interpreting the outcome.
What would make this wrong. The proposed explanation would be undermined if blocking muscle rebuilding erased the treatment's added lifespan benefit while the repair-supporting precursor cells retained normal numbers and fates. It would also be undermined if verified, selective correction of their accumulation before the proposed persistent state formed failed to restore that benefit, with muscle protein production still suppressed and the treatment's action elsewhere unchanged. Either observation would leave the supplied explanations involving processes inside muscle cells as alternatives; it would not establish which alternative is correct.
What it would change. If the prediction held, reproducing a useful fasting response would require managing the return of muscle repair-cell populations to their usual state between treatments. Development would therefore have to account for the completion of repair alongside the treatment's initial action. Even a successful lifespan rescue in the tested animals would leave applicability to humans, other treatments and other tissues unestablished; the supplied material also does not define the internal outcome label SPV_7, so its proposed stabilization cannot be interpreted.
Sources read · 8
“In a physiological response to injury, pro-inflammatory macrophages secrete TNF-alpha which induces apoptosis of fibro-adipogenic progenitors (FAPs) , and this prevents excessive FAP proliferation and collagen deposition.”
Does not settle: Источник не устанавливает влияние миметиков голодания, подавления мышечного анаболизма или сохранения фиброзно-жировых предшественников между повторными циклами на продолжительность жизни. Он также не показывает возвращение этих клеток к исходной численности, связь с SPV_7 и эффективность краткого избирательного ограничения их выживания.
Regulatory T cells require IL6 receptor alpha signaling to control skeletal muscle function and regeneration. · Cell metabolism · 2023
“As mesenchymal stromal cells, FAPs support SC differentiation during tissue regeneration.”
Does not settle: Источник не устанавливает, сохраняются ли фиброзно-жировые предшественники между циклами восстановления, возвращается ли их численность к исходному уровню и вызывает ли их сохранение фиброз. В нём также не исследованы миметики голодания, подавление мышечного анаболизма, избирательное ограничение выживания этих клеток, SPV_7 или продолжительность жизни.
MST1/2 regulates fibro/adipogenic progenitor fate decisions in skeletal muscle regeneration. · Stem cell reports · 2024
“This clearance of FAPs is critical for skeletal muscle regeneration, and if this does not occur, the non-apoptotic FAPs differentiate toward myofibroblasts under the action of transforming growth factor (TGF)-β1, eventually leading to collagen deposition and muscle fibrosis ( ).”
Does not settle: Источник описывает регенерацию скелетной мышцы после острого повреждения у мышей и подтверждает связь сохранения фиброзно-жировых предшественников с фиброзом. Он не исследует миметики голодания, продолжительность жизни, анаболическую фазу, воздействие в других тканях, повторные циклы лечения, показатель SPV_7 или способ кратковременного избирательного ограничения выживания этих клеток.
Musculoskeletal ultrasound-guided cellular therapy: Current applications and future directions in skeletal muscle regeneration. · Iranian journal of basic medical sciences · 2026
“Skeletal muscle exhibits robust intrinsic regeneration after acute injury, yet severe, chronic, or age-related damage commonly culminates in fibrosis, fatty infiltration, and lasting functional impairment.”
Does not settle: Источник не устанавливает влияние миметиков голодания, мышечного анаболизма или численности фиброзно-жировых предшественников между циклами восстановления на продолжительность жизни. Также он не проверяет избирательное ограничение выживания этих клеток или стабилизацию SPV_7.
Interleukin-15 facilitates muscle regeneration through modulation of fibro/adipogenic progenitors. · Cell communication and signaling : CCS · 2018
“In our study, we found treatment of IL-15 can enhance the fibrosis in injured muscle.”
Does not settle: Источник не устанавливает, сохраняются ли фиброзно-жировые предшественники между повторными циклами повреждения, зависят ли их сокращение и фиброз от мышечной анаболической фазы, влияет ли это на продолжительность жизни при применении миметика голодания и может ли краткое избирательное ограничение выживания этих клеток стабилизировать SPV_7.
Overexpression of PRDM16 improves muscle function after rotator cuff tears. · Journal of shoulder and elbow surgery · 2024
“Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle .”
Does not settle: Текст содержит только список литературы. Он не устанавливает влияние миметиков голодания на продолжительность жизни, динамику фиброзно-жировых предшественников между циклами восстановления, роль анаболической фазы, изменение SPV_7 или результат избирательного ограничения выживания стромальных клеток.
Phenotypic divergence in rotator cuff tear and volumetric muscle loss mouse models following fibroadipogenic progenitor depletion. · Bone & joint research · 2026
“The depletion of FAPs in RCTs attenuates fibrosis, FI, and muscle atrophy with improved global shoulder function. In TA VML, FAP depletion demonstrated decreased fibrosis, but no differences in muscle regeneration or functional outcomes.”
Does not settle: The source does not establish whether persistent FAPs erase lifespan gains from fasting mimetics. It does not study lifespan, fasting mimetics, anabolic-phase suppression, repeated injury cycles, post-repair return of FAP abundance to baseline, selective transient restriction of FAP survival, or SPV_7. Its findings are limited to FAP depletion in two mouse muscle-injury models at the reported follow-up.
Muscle-Derived Beige Adipose Precursors Secrete Promyogenic Exosomes That Treat Rotator Cuff Muscle Degeneration in Mice and Are Identified in Humans by Single-Cell RNA Sequencing. · The American journal of sports medicine · 2022
“Fibroadipogenic progenitors (FAPs) are multipotent resident muscle stem cells with the capacity to differentiate into fibrogenic as well as white and beige adipose tissue (BAT).”
Does not settle: Источник не устанавливает, сохраняются ли фиброзно-жировые предшественники между циклами повреждения, возвращается ли их численность к исходному уровню после восстановления мышечных волокон, зависит ли это от анаболической фазы или миметика голодания и влияет ли такая динамика на продолжительность жизни или SPV_7.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does a fasting-like treatment still extend life if muscle rebuilding cannot recover between treatments?
Original wording · exactly as the pipeline generated it
Сохранит ли миметик голодания продление жизни при избирательном устранении межциклового восстановления мышечного анаболизма, если подавление его основной мишени в остальных тканях остаётся прежним?
What this question is asking
The question asks whether a treatment's life-extending effect depends on muscles regaining their ability to build proteins between treatment cycles. It concerns a fasting mimetic, meaning a treatment intended to reproduce some effects of fasting, whose stated target is mechanistic target of rapamycin, or mTOR, a regulator of cell growth and metabolism. The comparison is between the same treatment with muscle recovery preserved and with that recovery selectively prevented, while target suppression in other tissues remains unchanged. The pipeline assumes that intermittent target suppression extends mouse lifespan and asks whether this benefit survives the loss of muscle recovery. Its stated recovery requirement is that muscles respond again by the next usual physical load and that repeated treatment does not lengthen their period of reduced responsiveness.
- Fasting mimetic
- A treatment intended to reproduce some biological effects of fasting. This names a class of intended effects, not a single substance or a guarantee that all effects of fasting are reproduced.
- Mechanistic target of rapamycin (mTOR)
- A regulator involved in cell growth and metabolism. The pipeline identifies its suppression as the treatment's main action.
- Mechanistic target of rapamycin complex 1
- A signaling assembly containing the target regulator that participates in controlling growth and protein building. S1 connects its activity to nutrient availability; S3 shows that sustained signaling need not mean sustained muscle protein production.
- Muscle anabolism or muscle rebuilding
- The building side of muscle maintenance, including production of muscle proteins. Recovery here means restoration of that building response between treatments, not necessarily a demonstrated increase in muscle size.
- Muscle protein synthesis
- The production of new proteins in muscle. It is a process contributing to muscle rebuilding, rather than a direct measurement of lifespan.
- Reduced responsiveness
- A smaller protein-building response despite continued stimulation. S3 describes this phenomenon, but does not establish its duration across the proposed treatment cycles.
- Essential amino acids and leucine
- Essential amino acids are protein building blocks that must come from the diet; leucine is one of them. S1 discusses their availability as an influence on growth-related signaling.
- Skeletal muscle and resistance training
- Skeletal muscles produce body movement. Resistance training loads these muscles against resistance, and S2 links their subsequent recovery to temporary increases in protein production.
- Ribosomes
- The cellular machinery that builds proteins. S4 relates their abundance to the capacity for muscle recovery after early undernutrition.
- Catch-up growth
- Accelerated growth during recovery from an earlier growth shortfall. In S4 it concerns development after undernutrition, rather than recovery between fasting-like treatment cycles.
- Myotis lucifugus and hibernation
- Myotis lucifugus is the bat species studied in S7. Hibernation includes periods of greatly reduced bodily activity; the supplied description concerns predicted signaling changes during that state.
- Rapamycin
- A substance described in S8 as inhibiting mechanistic target of rapamycin signaling. Its reported survival effect concerns the particular disease-model mice studied there.
- Fxn conditional inactivation and Friedreich ataxia model
- S8 concerns mice in which the gene identified as Fxn was switched off in selected tissues to model aspects of Friedreich ataxia, a disease. This specific altered background limits what its survival finding establishes about ordinary aging.
- RL-1
- An identifier supplied by the pipeline alongside its claim about intermittent target suppression and mouse lifespan. The provided material does not establish what it denotes.
Intermittent mTOR suppression, identified in the pipeline as RL-1, is associated with longer mouse lifespan, and muscle rebuilding recovers between cycles without a progressively longer period of reduced responsiveness.
The assumption concerns mice receiving repeated treatment that temporarily suppresses a regulator of cell growth. It treats longer life and recovery of muscle protein building before the next usual physical load as the starting conditions. If those conditions hold, the remaining question is whether removing muscle recovery removes the lifespan benefit.
The supplied sources do not establish this starting combination. S1 and S2 concern protein building around exercise, and S3 describes reduced responsiveness of muscle protein production despite continued nutrient availability and growth-related signaling. S8 reports improved survival after target suppression in mice with a specific disease-related genetic alteration, which does not establish longer natural lifespan under the intermittent treatment described here. The supplied search results contain no work establishing the RL-1 claim or stable recovery across repeated treatment cycles; this does not show that either claim is false.S1S2S3S8
The same question asked without the part nothing read establishes:
- During intermittent suppression of mechanistic target of rapamycin, does preventing muscle rebuilding from recovering between cycles change lifespan when suppression in other tissues stays the same?
- Does a fasting-like treatment's effect on lifespan depend on muscle rebuilding recovering between treatment cycles?
- The lifespan benefit is preserved If a lifespan benefit is first established and remains unchanged when muscle recovery is selectively prevented, that recovery would not be necessary for the benefit under those conditions. This would establish a separation between the lifespan outcome and that particular muscle response, without establishing that muscle health is unaffected.
- The lifespan benefit disappears If selective prevention of recovery removes an established lifespan benefit while suppression elsewhere stays unchanged, that would support a necessary contribution from muscle recovery under those conditions. Continued target suppression in other tissues would then be insufficient to preserve the benefit.
- The lifespan benefit becomes smaller If preventing recovery reduces but does not eliminate an established benefit, muscle recovery would contribute to its magnitude without accounting for all of it. The remaining extension of life would show that some benefit persists without that recovery, while leaving its explanation unsettled.
The proposed chain begins with temporary suppression of a growth-regulating target, followed by an interval in which muscle protein building can recover. Temporary increases in muscle protein production after exercise contribute to muscle growth, according to S2. Whether that recovery also helps preserve a treatment's lifespan benefit is a separate causal link that the supplied sources do not establish. If recovery is necessary, treating target suppression alone as sufficient would misidentify what produces the benefit. If recovery is unnecessary for that benefit, assuming otherwise would incorrectly make muscle recovery a condition for life extension.
Импульсное подавление mTOR, RL-1, связано с продлением жизни мышей; необходимость восстановительной фазы причинно не установлена.
Мышечный ответ восстанавливается до следующей обычной нагрузки; период нечувствительности не увеличивается при повторении.
Неизвестно, исчезает ли выигрыш продолжительности жизни при избирательном устранении восстановления и сохранении остальных эффектов миметика.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Продление жизни миметиком голодания требует завершения временной перестройки клеточного сообщества мышцы. Восстановившиеся мышечные волокна прекращают поддерживать среду хронического повреждения, после чего численность фиброзно-жировых предшественников возвращается к исходному уровню. Устранение анаболической фазы оставляет условия, в которых эти клетки сохраняются между циклами и постепенно переводят восстановление в фиброз. Поэтому выигрыш жизни исчезнет даже при неизменном подавлении основной мишени в остальных тканях. Новый миметик мог бы воспроизводить физиологическое сокращение временной стромальной популяции после ремонта, например посредством краткого, избирательного ограничения её выживания. Это стабилизировало бы SPV_7 при частично подавленном мышечном анаболизме.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Популяционная экология и экология сообществ; обобщённая модель Лотки — Вольтерры с периодическим воздействием: dN_i/dt = N_i[r_i + b_i A(t) + Σ_j a_ij N_j]. N_i и N_j обозначают измеряемые плотности миогенных предшественников, фиброзно-жировых предшественников и макрофагов в мышце, клеток/мм³; t обозначает время в сутках; r_i обозначает собственный темп изменения численности, сутки⁻¹; A(t) обозначает нормированную скорость синтеза белка в зрелых мышечных волокнах; b_i обозначает изменение темпа популяции на единицу A, сутки⁻¹; a_ij обозначает влияние плотности популяции j на темп популяции i, мм³/(клетка·сутки). Знаки взаимодействий устанавливаются экспериментально. Для редкой фиброгенной популяции F критерий закрепления равен g_F = T⁻¹∫₀ᵀ[r_F + b_F A(t) + Σ_j a_Fj N_j(t)]dt > 0, где T является длительностью цикла миметика. Гипотеза предсказывает, что устранение восстановительной фазы переводит g_F через ноль. Модель описывает закрепление популяции; влияние на продолжительность жизни требует отдельной проверки.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
После блокирования межциклового анаболизма численность фиброзно-жировых предшественников начнёт увеличиваться от цикла к циклу раньше выраженного фиброза. Избирательное возвращение их численности к физиологическому диапазону восстановит выигрыш жизни при сохранённом подавлении мышечного синтеза белка. Краткое восстановление анаболизма поможет только до закрепления патологической структуры сообщества. Если численность и судьба этих клеток остаются нормальными, а их избирательное ограничение не помогает, гипотеза уступает внутриклеточным механизмам.
Would tell it apart from at least one rival. The prediction specifies a temporal ordering, a conditional restoration of lifespan benefit, and an explicit rejection condition. These are measurable without numerical thresholds. No rival prediction was supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Доступны маркировка клеточных линий, пространственная гистология и генетическое управление стромальными популяциями. PDGFRα сам по себе недостаточно избирателен для системного вмешательства; необходимо подтвердить локальность воздействия и сохранение полезных предшественников.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
После блокирования межциклового анаболизма численность фиброзно-жировых предшественников начнёт увеличиваться от цикла к циклу раньше выраженного фиброза. Избирательное возвращение их численности к физиологическому диапазону восстановит выигрыш жизни при сохранённом подавлении мышечного синтеза белка. Краткое восстановление анаболизма поможет только до закрепления патологической структуры сообщества. Если численность и судьба этих клеток остаются нормальными, а их избирательное ограничение не помогает, гипотеза уступает внутриклеточным механизмам.
- Rival 01 of 04What would separate them
Mismatched ribosome assembly may make muscle recovery limit fasting-mimetic lifespan gains predicts: При подтверждённом подавлении межциклового синтеза белка мышечно-специфическое вмешательство увеличит дополнительный выигрыш жизни от миметика и уменьшит долю рибосомных белков вне собранных рибосом. Принудительное восстановление анаболического всплеска вернёт протеотоксичность и сократит этот выигрыш. Решающий результат: согласование сборки рибосом устранит вред всплеска при сохранении его амплитуды. Если блокирование восстановления сокращает жизнь при нормальной сборке рибосом, гипотеза уступает механизмам обязательного структурного или органелльного восстановления.
- What would separate them
Suppressing fatal disease outside muscle may preserve a mimetic’s lifespan benefit predicts: В факторном сравнении миметика и мышечного блокирования последнее ухудшит силу и анаболический ответ, но дополнительный выигрыш жизни от миметика сохранится в заранее установленной полосе эквивалентности. Снижение частоты или отсрочка смертельных опухолей также сохранится. Восстановление мышечной функции улучшит функциональные показатели, почти не изменив дополнительного выигрыша жизни. Гипотеза опровергается, если избирательное возвращение мышечного восстановления возвращает утраченный эффект миметика на выживаемость при сопоставимой патологии остальных тканей.
- What would separate them
Incomplete sarcomere repair may erase a fasting mimetic's lifespan benefit predicts: При одинаковом подавлении общего синтеза белка потеря эффекта миметика будет зависеть от механической нагрузки и сопровождаться незавершённой заменой филамина C в Z-дисках. Избирательное восстановление его встраивания улучшит удельную силу и сохранит выигрыш жизни при низком общем анаболизме. Нормализация только численности стромальных клеток или только лизосомного цикла окажется недостаточной. Сохранность Z-дисков и отсутствие зависимости от нагрузки при утрате выигрыша жизни опровергнут этот механизм.
- What would separate them
Failed lysosome reformation may erase a fasting mimic's lifespan benefit predicts: Продолжительное подавление мышечного mTORC1 уменьшит повторное образование лизосом, ухудшит деградацию аутофагического груза в поздних циклах и устранит выигрыш жизни. При сопоставимом подавлении синтеза белка через отдельную трансляционную ветвь, сохраняющую лизосомный цикл, выигрыш останется. Восстановление именно преобразования мембран аутолизосом вернёт эффект миметика при низком анаболизме. Если оба способа подавления трансляции одинаково сокращают жизнь при нормальной лизосомной функции, гипотеза уступает структурному механизму.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.